Abstract
The existence of long-lasting cellular reservoirs of HIV-1 is one of the major hurdles in developing effective anti-retroviral therapies. These latently infected cells and tissues efficiently evade immune responses and remain dormant until activated, upon which they can generate a productive HIV-1 infection. This classic scenario of viral latency becomes even more difficult to study and model due to the extreme complexity of translating in vivo virus-cell interactions into a controlled in vitro system. The recent developments and constant improvements upon hematopoietic engraftment of human cells and tissues onto recipient immunocompromised murine scaffolds have made it possible to model complex human innate and adaptive immune responses in a small animal model. Specifically, HIV-1 infection has been successfully modeled in these humanized mice to mimic transmission, pathogenesis, host immune responses, and treatment. Here, we review the complexities surrounding modeling HIV-1 latency in vitro and in vivo and highlight the most recent humanized mouse models that support retroviral infection.
Keywords: HIV-1, latency, HAART, humanized mouse model, HIV INFECTIONS, HIV-1 LATENCY, Primary Cells, Transformed cell lines, Small Animal Models, Latent reservoirs
Current HIV Research
Title: Humanized Mouse Models of HIV-1 Latency
Volume: 9 Issue: 8
Author(s): Rachel V. Duyne, Aarthi Narayanan, Kylene K.-Hall, Mohammed Saifuddin, Leonard Shultz and Fatah Kashanchi
Affiliation:
Keywords: HIV-1, latency, HAART, humanized mouse model, HIV INFECTIONS, HIV-1 LATENCY, Primary Cells, Transformed cell lines, Small Animal Models, Latent reservoirs
Abstract: The existence of long-lasting cellular reservoirs of HIV-1 is one of the major hurdles in developing effective anti-retroviral therapies. These latently infected cells and tissues efficiently evade immune responses and remain dormant until activated, upon which they can generate a productive HIV-1 infection. This classic scenario of viral latency becomes even more difficult to study and model due to the extreme complexity of translating in vivo virus-cell interactions into a controlled in vitro system. The recent developments and constant improvements upon hematopoietic engraftment of human cells and tissues onto recipient immunocompromised murine scaffolds have made it possible to model complex human innate and adaptive immune responses in a small animal model. Specifically, HIV-1 infection has been successfully modeled in these humanized mice to mimic transmission, pathogenesis, host immune responses, and treatment. Here, we review the complexities surrounding modeling HIV-1 latency in vitro and in vivo and highlight the most recent humanized mouse models that support retroviral infection.
Export Options
About this article
Cite this article as:
V. Duyne Rachel, Narayanan Aarthi, K.-Hall Kylene, Saifuddin Mohammed, Shultz Leonard and Kashanchi Fatah, Humanized Mouse Models of HIV-1 Latency, Current HIV Research 2011; 9 (8) . https://dx.doi.org/10.2174/157016211798998781
DOI https://dx.doi.org/10.2174/157016211798998781 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Involvement of Membrane Channels in Autoimmune Disorders
Current Pharmaceutical Design Invasion and Egress by the Obligate Intracellular Parasite Toxoplasma gondii: Potential Targets for the Development of New Antiparasitic Drugs
Current Pharmaceutical Design The Non-Canonical IκB Kinases IKKε and TBK1 as Potential Targets for the Development of Novel Therapeutic Drugs
Current Molecular Medicine Amyloid β -Protein Assembly as a Therapeutic Target of Alzheimers Disease
Current Pharmaceutical Design Gene Therapy and Biologic Therapy with Interleukin?4
Current Gene Therapy Early Diagnosis of Multiple Sclerosis Based on Optical and Electrochemical Biosensors: Comprehensive Perspective
Current Analytical Chemistry Pentapeptides as Minimal Functional Units in Cell Biology and Immunology
Current Protein & Peptide Science Crossed Cerebellar Diaschisis in Alzheimer’s Disease
Current Alzheimer Research The RNA-Dependent-RNA Polymerase, an Emerging Antiviral Drug Target for the Hendra Virus
Current Drug Targets Mouse Models of Multiple Sclerosis: Lost in Translation?
Current Pharmaceutical Design Enhancing the Delivery of Anti Retroviral Drug “Saquinavir” Across the Blood Brain Barrier Using Nanoparticles
Current HIV Research Genetically Modified Viruses Vaccines by Design
Current Pharmaceutical Biotechnology Synthetic and Natural Protease Inhibitors Provide Insights into Parasite Development, Virulence and Pathogenesis
Current Medicinal Chemistry True or False? Activations of Language-related Areas in Patients with Disorders of Consciousness
Current Pharmaceutical Design Regulation of Protective and Pathogenic Th17 Responses
Current Immunology Reviews (Discontinued) Conventional (Continuous) EEG Monitoring in the NICU
Current Pediatric Reviews Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem
Current Drug Targets New Insights into Chemistry and Anti-Infective Potential of Triazole Scaffold
Current Medicinal Chemistry Drug Target Discovery Through Analysis of Laccase Regulatory Networks of Cryptococccus neoformans
Current Enzyme Inhibition Intracellular Amyloid β-Protein and Its Associated Molecules in the Pathogenesis of Alzheimers Disease
Mini-Reviews in Medicinal Chemistry